CaaMTech Partners With NIH to Study Synthetic Tryptamines

This collaboration will study a full spectrum of pharmacological effects of several synthetic tryptamine compounds.

The pharmaceutical company CaaMTech has announced that they are collaborating with the Designer Drug Research Unit (DDRU) at the National Institute on Drug Abuse (NIDA) Intramural Research Program (IRP), which is part of the National Institutes of Health (NIH). The partnership will be researching the effects and physiological mechanisms of tryptamine-based compounds synthesized by CaaMTech (naturally occurring tryptamine compounds include psychedelic compounds such as psilocinibogaine, and 5-MeO-DMT).

CaaMTech says in the press release that this collaboration will finally provide what psychedelic drug research requires  – determining the pharmacological properties of synthetic tryptamines. Understanding these compounds at the molecular and receptor level is essential for creating formulations with specific amounts of compounds.

CaaMTech CEO Dr. Andrew Chadeayne said, “Psilocybin is just the first of many psychedelic tryptamine-based compounds to receive meaningful scientific attention. Now that we have a library of reliable compounds, our goal is to increase the number of candidates available for clinical trials by filling in much-needed information about their pharmacological properties. We look forward to advancing the best candidates into an FDA approval process to ultimately improve the available options for treating mental health disorders.”